European Journal of Surgical Oncology
Volume 36, Issue 7 , Pages 610-616 , July 2010

Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: A retrospective audit

  • T. Hølmebakk

      Affiliations

    • Department of Surgical Gastroenterology, Oslo University Hospital, Aker, 0514 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 22 89 40 00; fax: +47 22 22 56 48.
    • ,
  • G. Frykholm

      Affiliations

    • Department of Oncology, St. Olav's Hospital, 7006 Trondheim, Norway
    • Norwegian University of Science and Technology, 7491 Trondheim, Norway
    • ,
  • A. Viste

      Affiliations

    • Department of Surgery, Haukeland University Hospital, 5053 Bergen, Norway
    • Department of Surgical Sciences, University of Bergen, 5053 Bergen, Norway
    • ,
  • on behalf of the Norwegian Gastrointestinal Cancer Group (NGICG)

,Accepted 4 May 2010.

References 

  1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20
  2. Helsedirektoratet . Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med magekreft. www.helsedirektoratet.no/publikasjoner/nasjonale_faglige_retningslinjer
  3. The Norwegian Cancer Registry . Cancer in Norway. 2008;www.kreftregisteret.no/no/Generelt/Publikasjoner/Cancer-in-Norway/Cancer-in-Norway-2008/
  4. Birkmeyer JD, Sun Y, Wong SL, et al. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777–783
  5. Preacher KJ. Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. 2001, April;www.quantpsy.org
  6. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007;25(18S):4510;Abstract
  7. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5(7):609–616
  8. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995;13(2):424–429
  9. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advance esophagogastric cancer. J Clin Oncol. 1997;15(1):261–267
  10. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46
  11. In:  Sobin LH,  Wittekind CH editor. International Union Against Cancer (UICC): TNM classification of malignant tumours. 6th ed.. New York: John Wiley; 2002;
  12. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–2116
  13. Yan C, Zhu ZG, Yan M, et al. Value of multidetector-row computed tomography in preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol. 2009;100(3):205–214
  14. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22
  15. Stockeld D, Tennvall J, Wagenius G, et al. A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncol. 2001;40(5):566–573
  16. Wiig JN, Larsen SG, Dueland S, et al. Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol. 2005;92(1):70–75
  17. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009;96:26–33
  18. Thompson AM, Rapson T, Gilbert FJ, et al. for the Scottish audit of gastric and oesophageal cancer, Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer. Br J Surg. 2007;94:578–584
  19. McCulloch P, Ward J, Tekkis PP, ASCOT Group of Surgeons , British Oesophago-Gastric Cancer Group . Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327:1192–1197
  20. Lepage C, Sant M, Verdecchia A, et al. for the EUROCARE Working Group. Operative mortality after gastric cancer resection and long-term survival differences across Europe. Brit J Surg. 2010;97:235–239
  21. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–2127
  22. Damhuis RA, Meurs CJ, Dijkhuis CM, et al. Hospital volume and post-operative mortality after resection for gastric cancer. Eur J Surg Oncol. 2002;28:401–405
  23. Skipworth RJE, Parks RW, Stephens NA, et al. The relationship between hospital volume and post-operative mortality rates for upper gastrointestinal cancer resections: Scotland 1982–2003. Eur J Surg Oncol. 2010;36:141–147
  24. Wibe A, Møller B, Norstein J, et al. A national strategic change in treatment policy for rectal cancer-implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002;45(7):857–866
  25. Martling A, Holm T, Rutqvist H, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005;92:225–229

PII: S0748-7983(10)00114-9

doi: 10.1016/j.ejso.2010.05.006

European Journal of Surgical Oncology
Volume 36, Issue 7 , Pages 610-616 , July 2010

Article Tools